Until the widespread adoption of specific prophylaxis in thelate 1980s, Pneumocystis carinii pneumonia was among the mostcommon life-threatening opportunistic infections associatedwith infection with the human immunodeficiency virus (HIV) inindustrialized countries. Primary prophylaxis against P. cariniipneumonia is currently recommended for all HIV-infected patientswith CD4 cell counts of less than 200 per cubic millimeter andfor those receiving cytotoxic chemotherapy. Secondary prophylaxisis recommended for all patients with a history of P. cariniipneumonia.1
The advent of highly active antiretroviral therapy, which candrastically inhibit HIV replication and lead to substantialincreases in CD4 cell counts, . . . [Full Text of this Article]
References
This article has been cited by other articles:
Atzori, C., Clerici, M., Trabattoni, D., Fantoni, G., Valerio, A., Tronconi, E., Cargnel, A.
(2003). Assessment of immune reconstitution to Pneumocystis carinii in HIV-1 patients under different highly active antiretroviral therapy regimens. J Antimicrob Chemother
52: 276-281
[Abstract][Full Text]
Bender, M. A., Sax, P. E., Le Moal, G., Breux, J.-P., Roblot, F., Lopez Bernaldo de Quiros, J. C., Miro, J. M., Pena, J. M., Lundgren, J., Reiss, P., Ledergerber, B.
(2001). Discontinuing Prophylaxis against Pneumocystis carinii Pneumonia. NEJM
344: 1639-1641
[Full Text]